Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

NCT04539262 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04539262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04539262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
September 14, 2020
Completion date
March 22, 2021
Enrollment
156 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19